Erythema Nodosum

Comprehensive Clinical Guide: Erythema Nodosum (EN)

1. Introduction and Clinical Overview

Erythema Nodosum (EN) represents the most common form of panniculitis—an inflammatory condition affecting the subcutaneous fat layer. Clinically, it manifests as acute, tender, erythematous, nodular lesions, typically localized to the pretibial surfaces of the lower extremities.

While EN is often self-limiting, it serves as a critical cutaneous marker for underlying systemic disease. It is categorized as a hypersensitivity reaction, often triggered by infections, medications, malignancies, or chronic inflammatory conditions. As an orthopedic and clinical specialist, it is imperative to view EN not merely as a dermatological curiosity, but as a potential "red flag" requiring a rigorous diagnostic workup to uncover latent systemic pathologies.

2. Etiology and Pathophysiological Mechanisms

The pathogenesis of Erythema Nodosum is characterized by a delayed-type hypersensitivity reaction (Type IV) directed against various antigenic stimuli. The inflammatory process is primarily localized to the septa of the subcutaneous fat (septal panniculitis) without primary involvement of the fat lobules.

Key Etiological Categories

The Mechanism of Action

The immune system reacts to circulating antigens that deposit in the subcutaneous septa. This triggers the activation of T-lymphocytes and the release of pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α). The resulting vasculitis and septal inflammation lead to the characteristic clinical presentation of "tender nodules."

3. Clinical Presentation and Staging

The clinical course of Erythema Nodosum is usually acute, though it can transition into a subacute or chronic phase (Erythema Nodosum Migrans).

Standard Presentation

1. Prodromal Phase: Often presents 1–3 weeks prior to skin lesions with fever, malaise, arthralgia, and upper respiratory symptoms.
2. Cutaneous Lesions: Bilateral, symmetric, tender, erythematous nodules. They are typically 1–5 cm in diameter.
3. Distribution: Pretibial surfaces are the classic site, but lesions may appear on the thighs, calves, forearms, or face (rarely).
4. Evolution: Lesions do not ulcerate. They evolve in color from bright red to a bruised appearance (violaceous, then brownish-yellow) as they resolve over 3–6 weeks, similar to the resolution of a hematoma (erythema contusiformis).

Clinical Grading/Severity

While no formal universal staging system exists, clinical severity is often assessed by:
* Mild: Localized pretibial nodules, minimal systemic symptoms.
* Moderate: Multiple lesions, significant pain affecting gait, moderate arthralgia.
* Severe: Extensive nodules, high-grade fever, debilitating arthralgia/arthritis, and systemic involvement (e.g., hilar adenopathy in Sarcoidosis).

4. Differential Diagnosis

Distinguishing EN from other forms of panniculitis is essential for clinical accuracy.

• Erythema Induratum (Nodular Vasculitis): Typically involves the posterior calves, often ulcerates, and is strongly associated with tuberculosis.
• Cellulitis: Usually unilateral, ill-defined borders, associated with warmth and lymphangitis; EN is bilateral and better defined.
• Polyarteritis Nodosa (PAN): Features subcutaneous nodules but is associated with livedo reticularis, ulceration, and systemic organ involvement (kidneys/nerves).
• Septal Panniculitis (Other types): Specifically, necrobiosis lipoidica or superficial thrombophlebitis.

5. Diagnostic Workup and Testing

The diagnosis is primarily clinical, but a workup is mandatory to identify the underlying etiology.

1. Laboratory Investigations:
2. CBC with Differential: Assessing for leukocytosis or lymphocytosis.
3. Inflammatory Markers: ESR (Erythrocyte Sedimentation Rate) and CRP are almost always elevated.
4. Antistreptolysin O (ASO) Titer/Anti-DNase B: To rule out recent Streptococcal infection.
5. QuantiFERON-TB Gold: To screen for latent or active Tuberculosis.
6. Imaging:
7. Chest X-Ray (CXR): Crucial to evaluate for bilateral hilar adenopathy, which suggests Sarcoidosis or TB.
8. Histopathology (The Gold Standard):
9. If the diagnosis is ambiguous, a deep wedge biopsy is required.
10. Histological Hallmarks: Septal panniculitis with minimal fat necrosis, Miescher’s radial granulomas (small, stellate-shaped granulomas), and thickened septa.

6. Management and Therapeutic Approaches

Management focuses on treating the underlying cause and alleviating symptoms.

• Conservative Therapy: Bed rest, leg elevation, and compression stockings are the first-line recommendations to manage edema and pain.
• Pharmacotherapy:
  • NSAIDs: Indomethacin or Naproxen are highly effective for reducing inflammation and pain.
  • Potassium Iodide: A classic, highly effective treatment for persistent EN, particularly when the etiology is unknown.
  • Systemic Corticosteroids: Reserved for severe or recalcitrant cases after infectious causes (especially TB/fungal) have been ruled out.
  • Colchicine: Useful in chronic or recurrent cases.

7. Risks, Prognosis, and Long-Term Outlook

• Prognosis: Excellent. Most cases resolve spontaneously within 6 weeks without scarring.
• Recurrence: Possible if the underlying systemic trigger is not addressed.
• Risks: The primary risk is not the skin lesion itself, but the missed diagnosis of an underlying systemic infection (e.g., TB) or autoimmune condition (e.g., Crohn’s).

8. Massive FAQ Section

1. Is Erythema Nodosum contagious?
No. EN is an immune-mediated hypersensitivity reaction, not an infection. You cannot catch it from someone else.

2. Why are the nodules so painful?
The pain is caused by the intense inflammatory response in the septa of the subcutaneous fat, which is highly vascularized and contains nerve endings.

3. Does EN ever lead to cancer?
EN itself is not a cancer. However, it can be a paraneoplastic sign of an underlying malignancy, such as lymphoma, although this is rare.

4. Can I exercise while having Erythema Nodosum?
High-impact exercise is generally discouraged during the acute phase, as it can exacerbate swelling and pain in the legs. Rest is recommended.

5. How long does it take for the nodules to go away?
Most lesions resolve in 3–6 weeks. They fade from red to a bruised, brownish color before disappearing completely.

6. Do I need a biopsy for every case?
No. In classic presentations (bilateral pretibial tender nodules), the diagnosis is clinical. Biopsy is reserved for atypical cases or when the diagnosis remains uncertain.

7. Why is a Chest X-ray mandatory?
Because EN is a common initial manifestation of Sarcoidosis (Löfgren syndrome) and Tuberculosis. A chest X-ray can detect hilar adenopathy associated with these conditions.

8. Is there a link between birth control pills and EN?
Yes. Oral contraceptives, specifically those containing estrogen, are a well-documented pharmacological trigger for EN.

9. Can children get Erythema Nodosum?
Yes, though it is more common in adults aged 20–40. In children, it is most frequently triggered by a recent streptococcal infection.

10. Will the nodules leave scars?
Typically, no. Once the inflammation subsides, the skin usually returns to its normal state. Pigmentation changes may persist for a short time but generally fade.

9. Conclusion for Clinicians

Erythema Nodosum serves as a diagnostic bridge between dermatology and internal medicine. While the cutaneous findings are often self-limiting, the clinician’s responsibility lies in the "hunt" for the trigger. By systematically evaluating for infection, drug exposure, and autoimmune activity, the orthopedic and primary care provider can ensure that the patient receives not just symptomatic relief, but comprehensive management of the underlying systemic health status. Always prioritize the exclusion of TB and Streptococcal infections before initiating systemic anti-inflammatory therapy.